Cellectar Biosciences INC NEW
CLRBStock
$2.58−47.19%52W
Market Cap$21.02M
P/E—
Div yield—
Beta0.55
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-27.00%
Price vs S&P 500 (4W)12.79%
VGM Score29.07
Market Capitalization$21.02M
Earnings Surprise History
Q1 26-1.30est. -1.92
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.11
4.13
4.13
4.22
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CLRBCellectar Biosciences INC NEW | F | — | D | $2.58 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Cellectar Biosciences is a clinical-stage biopharmaceutical company developing cancer therapeutics using its proprietary phospholipid drug conjugate (PDC) delivery platform. The company's PDC technology is designed to selectively target cancer cells, potentially offering improved efficacy with reduced off-target toxicity compared to conventional approaches. Cellectar is leveraging this platform to build a pipeline of oncology drugs aimed at addressing unmet patient needs in cancer treatment.